Constipation prevalence and fatigue severity in regular kratom (Mitragyna speciosa Korth.) users

References

• Anwar, M., Law, R., & Schier, J. (2016). Notes from the field: Kratom (Mitragyna speciosa) exposures reported to poison centers-United States, 2010-2015. CDC, 65(29), 748–749.
   Google Scholar
• Assanangkornchai, S., Muekthong, A., Sam-Angsri, N., & Pattanasattayawong, U. (2007). The use of mitragynine speciosa (“Krathom”), an addictive plant, in Thailand. Substance Use & Misuse, 42(14), 2145–2157. doi:10.1080/10826080701205869
   PubMed Web of Science ®Google Scholar
• Bawor, M., Bami, H., Dennis, B. B., Plater, C., Worster, A., Varenbut, M., … Samaan, Z. (2015). Testosterone suppression in opioid users: A systematic review and meta-analysis. Drug & Alcohol Dependence, 149, 1–9. doi:10.1016/j.drugalcdep.2015.01.038
   PubMed Web of Science ®Google Scholar
• Bell, T. J., Panchal, S. J., Miaskowski, C., Bolge, S. C., Milanova, T., & Williamson, R. (2009). The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European Patient Survey (PROBE 1). Pain Medicine, 10, 35–42. doi:10.1111/j.1526-4637.2008.00495.x
   PubMed Web of Science ®Google Scholar
• Chittrakarn, S., Sawangjaroen, K., Prasettho, S., Janchawee, B., & Keawpradub, N. (2008). Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tract. Journal of Ethnopharmacology, 116, 173–178. doi:10.1016/j.jep.2007.11.032
   PubMed Web of Science ®Google Scholar
• Griffin, O. H., & Webb, M. E. (2017). The scheduling of kratom and selective use of data. Journal of Psychoactive Drugs, 50(5), 1–7.
   Google Scholar
• Grundmann, O. (2017). Patterns of kratom use and health impact in the US-Results from an online survey. Drug and Alcohol Dependence, 176, 63–70. doi:10.1016/j.drugalcdep.2017.03.007
   PubMed Web of Science ®Google Scholar
• Hemby, S. E., McIntosh, S., Leon, F., Cutler, S. J., & McCurdy, C. R. (2018). Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addiction Biology, 21(1), 98-110.
   PubMed Web of Science ®Google Scholar
• Henningfield, J. E., Fant, R. V., & Wang, D. W. (2017). The abuse potential of kratom according the 8 factors of the controlled substances act: Implications for regulation and research. Psychopharmacology, 235(2): 573-589.
   Web of Science ®Google Scholar
• Kapp, F. G., Maurer, H. H., Auwärter, V., Winkelmann, M., & Hermanns-Clausen, M. (2011). Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). Journal of Medical Toxicology, 7(3), 227–231. doi:10.1007/s13181-011-0155-5
   PubMedGoogle Scholar
• Katz, N., & Mazer, N. A. (2009). The impact of opioids on the endocrine system. The Clinical Journal of Pain, 25(2), 170–175. doi:10.1097/AJP.0b013e3181850df6
   PubMed Web of Science ®Google Scholar
• Kronstrand, R., Roman, M., Thelander, G., & Eriksson, A. (2011). Unintentional fatal intoxications with mitragynine and O-Desmethyltramadol from the herbal blend krypton. Journal of Analytical Toxicology, 35, 242–247.
   PubMed Web of Science ®Google Scholar
• Kruegel, A. C., Gassaway, M. M., Kapoor, A., Varadi, A., Majumdar, S., Filizola, M., … Sames, D. (2016). Synthetic and receptor signaling exploration of the Mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. Journal of the American Chemical Society, 138, 6754–6764. doi:10.1021/jacs.6b00360
   PubMed Web of Science ®Google Scholar
• Kruegel, A. C., & Grundmann, O. (2017). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134, 108-120.
   PubMed Web of Science ®Google Scholar
• Krupp, L.B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The fatigue severity scale application to patients with multiple sclerosis and systemic lupus erythematosus. Archives Of Neurology, 46, 1121-1123.
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Hatori, Y., Murayama, T., Tashima, K., Wongseripipatana, S., Misawa, K., … Horie, S. (2006). Involvement of μ-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa. European Journal of Pharmacology, 549, 63–70. doi:10.1016/j.ejphar.2006.08.013
   PubMed Web of Science ®Google Scholar
• Matsumoto, K., Takayama, H., Narita, M., Nakamura, A., Suzuki, M., Suzuki, T., … Horie, S. (2008). MGM-9 [(E)-methyl 2-(3-ethyl-7a,12a-(epoxyethanoxy)-9-fluoro-1,2,3,4,6,7,12,12b-octahydro-8-methoxyindolo[2,3-a]quinolizin-2-yl)-3-methoxyacrylate], a derivative of the indole alkaloid mitragynine: A novel dual acting μ- and κ-opioid agonist with potent antinociceptive and weak rewarding effects in mice. Neuropharmacology, 55, 154–165. doi:10.1016/j.neuropharm.2008.05.003
   PubMed Web of Science ®Google Scholar
• McMillan, S.C., & Williams, F.A. (1989). Validity and reliability of the constipation assessment scale. Cancer Nursing, 12(3), 183–8.
   PubMed Web of Science ®Google Scholar
• Panchal, S. J., Müller‐Schwefe, P. J. I. W., & Wurzelmann, J. I. (2007). Opioid‐induced bowel dysfunction: Prevalence, pathophysiology and burden. International Journal of Clinical Practice, 61(7), 1181–1187. doi:10.1111/j.1742-1241.2007.01415.x
   PubMed Web of Science ®Google Scholar
• Pinney Associates. (2016). Assessment of kratom under the CSA eight factors and scheduling recommendation. Retrieved from http://www.pinneyassociates.com/wp-content/uploads/2017/07/Kratom-8-Factor-by-PinneyAssoc-11.28.16.pdf
   Google Scholar
• Prozialeck, W. C. (2016). Update on the pharmacology and legal status of kratom. The Journal Of The American Osteopathic Association, 116(12), 802-809.
   PubMed Web of Science ®Google Scholar
• Rajagopal, A., Vassilopoulou‐Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2004). Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer, 100(4), 851–858. doi:10.1002/cncr.20028
   PubMed Web of Science ®Google Scholar
• Saingam, D., Assanangkornchai, S., Geater, A. F., & Balthip, Q. (2012). Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: A qualitative study. International Journal of Drug Policy, 24(4), 351–358. doi:10.1016/j.drugpo.2012.09.004
   PubMed Web of Science ®Google Scholar
• Singh, D., Müller, C. P., Murugaiyah, V., Hamid, S. B. S., Vicknasingam, B. K., Avery, B., … Mansor, S. M. (2018a). Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. Journal of Ethnopharmacology, 214, 197–206. doi:10.1016/j.jep.2017.12.017
   PubMed Web of Science ®Google Scholar
• Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug & Alcohol Dependence, 139, 132–137. doi:10.1016/j.drugalcdep.2014.03.017
   PubMed Web of Science ®Google Scholar
• Singh, D., Müller, C. P., Vicknasingam, B. K., & Mansor, S. M. (2015). Social functioning of Kratom (Mitragyna speciosa) users in Malaysia. Journal of Psychoactive Drugs, 47(2), 125–131. doi:10.1080/02791072.2015.1012610
   PubMed Web of Science ®Google Scholar
• Singh, D., Murugaiyah, V., Hamid, S. B. S., Kasinather, V., Chan, M. S. A., Ho, E. T. W., … Mansor, S. M. (2018b). Assessment of gonadotropins and testosterone hormone levels in regular Mitragyna speciosa (Korth.) users. Journal of Ethnopharmacology, 221, 30–36. doi:10.1016/j.jep.2018.04.005
   PubMed Web of Science ®Google Scholar
• Singh, D., Narayanan, S., & Vicknasingam, B. (2016). Traditional and non-traditional uses of Mitragynine (Kratom): A survey of the literature. Brain Research Bulletin, 126, 41–46. doi:10.1016/j.brainresbull.2016.05.004
   PubMed Web of Science ®Google Scholar
• Singh, D., Narayanan, S., Vicknasingam, B. K., Prozialeck, W. C., Ramanathan, S., Zainal, H., & Harun, S. N. (2018c). Severity of pain and sleep problems during Kratom (Mitragyna speciosa Korth.) cessation among regular Kratom users. Journal of Psychoactive Drugs, 1–9. doi:10.1080/02791072.2018.1511879
   Web of Science ®Google Scholar
• Smith, H. S., & Elliott, J. A. (2012). Opioid-induced androgen deficiency (OPIAD). Pain Physician, 15(Supplement 3), ES145–56.
   PubMed Web of Science ®Google Scholar
• Suwanlert, S. (1975). A study of kratom eaters in Thailand. Bulletin on Narcotics, 27(3), 21–27.
   PubMedGoogle Scholar
• Vallerand, A. H. (2017). Opioid-induced Constipation. The Journal for Nurse Practitioners, 13(2), 170–174. doi:10.1016/j.nurpra.2016.11.006
   Google Scholar
• Varadi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabo, M. R., Rouzic, V. L., … Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesic with Mu Agoism and Delta Antagonism, which do not recruit β-Arrestin-2. Journal of Medical Chemistry, 59(18), 8381–8397. doi:10.1021/acs.jmedchem.6b00748
   PubMed Web of Science ®Google Scholar
• Vicknasingam, B., Narayanan, S., Beng, G. T., & Mansor, S. M. (2010). The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. International Journal of Drug Policy, 21, 283–288. doi:10.1016/j.drugpo.2009.12.003
   PubMed Web of Science ®Google Scholar
• Yue, K., Kopajtic, T. A., & Katz, J. L. (2018). Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology. doi:10.1007/s00213-018-4974-9
   PubMed Web of Science ®Google Scholar